Full history for every metric is available with a Kvantra account
Tetra Bio-Pharma Inc. (TBP.TO)
Key financial summary
Financials in CAD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CAD m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | CAD m | -25 | -11 | |||||
| Net profit | CAD m | -1 | -6 | -8 | -16 | -27 | -53 | -39 |
| EPS reported | CAD | -0.12 | -0.10 | |||||
| Operating cashflow per share | CAD | -0.06 | -0.06 | |||||
| Capex per share | CAD | 0.00 | 0.00 | |||||
| FCF per share | CAD | -0.06 | -0.06 | |||||
| Free cash flow | CAD m | -26 | -8 | |||||
| Net debt | CAD m | -2 | 1 | |||||
| Book value equity | CAD m | - | - | |||||
| Book value per share | CAD | 0.00 | - | |||||
| Number of shares | m | 445.7 | 423.36 | |||||
| DPS (TTM paid) | CAD | 0.00 | 0.00 |
Financial summary
Financials in CAD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 393.26 | 44.69 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -3.71 | -1.29 | |||||
| EV/EBITDA LTM | x | -1.92 | -0.97 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -54.48% | -479.42% | |||||
| FCF Yield | % | -26.96% | -77.62% | |||||
| Quality | ||||||||
| ROE | % | -21424.8% | -467.81% | |||||
| ROIC | % | -739.13% | -739.13% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -8.49 | -4.95 | |||||
| Net Debt/EBITDA | x | 0.04 | 0.04 | |||||
| EBIT/Net interest | x | -13.11 | -13.11 | |||||
| Net debt/market cap | % | -1.81% | 11.12% | |||||
| Net debt/Equity | x | - | - | |||||
| Gross debt/equity | x | - | - | |||||
Company overview
Headquartered in Orléans, Canada, Tetra Bio-Pharma Inc. is a biopharmaceutical company focused on discovering and developing cannabinoid-based medications. Their efforts span several therapeutic areas, including inflammation, pain management, ophthalmology, and oncology. The company's pipeline features various drug candidates: PLENITUDE is being developed for cancer-related pain in advanced patients, while REBORN addresses breakthrough cancer pain. Reduvo is designed to combat chemotherapy-induced nausea and vomiting. ARDS-003 targets sepsis and the prevention of acute respiratory distress syndrome, and SERENITY aims to treat cancer cachexia. Furthermore, Tetra Bio-Pharma is advancing PPP003 for painful dry eye and uveitis pain, and HCC011 for hepatocellular carcinoma.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Tetra Bio-Pharma Inc. (TBP.TO)
Headquartered in Orléans, Canada, Tetra Bio-Pharma Inc. is a biopharmaceutical company focused on discovering and developing cannabinoid-based medications. Their efforts span several therapeutic areas, including inflammation, pain management, ophthalmology, and oncology. The company's pipeline features various drug candidates: PLENITUDE is being developed for cancer-related pain in advanced patients, while REBORN addresses breakthrough cancer pain. Reduvo is designed to combat chemotherapy-induced nausea and vomiting. ARDS-003 targets sepsis and the prevention of acute respiratory distress syndrome, and SERENITY aims to treat cancer cachexia. Furthermore, Tetra Bio-Pharma is advancing PPP003 for painful dry eye and uveitis pain, and HCC011 for hepatocellular carcinoma.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free